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Aims The aim of this study was to evaluate the clinical efficacy and safety of remote monitoring in patients with heart
failure implanted with a biventricular defibrillator (CRT-D) with advanced diagnostics.
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Methods
and results
The MORE-CARE trial is an international, prospective, multicentre, randomized controlled trial. Within 8 weeks of de
novo implant of a CRT-D, patients were randomized to undergo remote checks alternating with in-office follow-ups
(Remote arm) or in-office follow-ups alone (Standard arm). The primary endpoint was a composite of death and
cardiovascular (CV) and device-related hospitalization. Use of healthcare resources was also evaluated. A total of
865 eligible patients (mean age 66±10 years) were included in the final analysis (437 in the Remote arm and 428 in
the Standard arm) and followed for a median of 24 (interquartile range=15–26) months. No significant difference was
found in the primary endpoint between the Remote and Standard arms [hazard ratio 1.02, 95% confidence interval
(CI) 0.80–1.30, P = 0.89] or in the individual components of the primary endpoint (P > 0.05). For the composite
endpoint of healthcare resource utilization (i.e. 2-year rates of CV hospitalizations, CV emergency department
admissions, and CV in-office follow-ups), a significant 38% reduction was found in the Remote vs. Standard arm
(incidence rate ratio 0.62, 95% CI 0.58–0.66, P < 0.001) mainly driven by a reduction of in-office visits.
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Conclusions In heart failure patients implanted with a CRT-D, remote monitoring did not reduce mortality or risk of CV or
device-related hospitalization. Use of healthcare resources was significantly reduced as a result of a marked reduction
of in-office visits without compromising patient safety.
Trial registration: NCT00885677
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Introduction
Heart failure (HF) is a frequent disease in developed countries
and is associated with increased mortality and morbidity, quality
of life impairment, and heavy healthcare and economic burden.
Data from the ESC-HF Pilot survey1 conducted in 12 European
countries showed post-discharge mortality and readmission rates
at 1 year of 17.4% and 31.9%, respectively. More recent data
confirmed the important clinical and economic burden of HF
hospitalizations.2,3
Cardiac resynchronization therapy (CRT) has been shown to
reduce mortality and rehospitalization in selected HF patients.4,5
A recent study from a real-world cohort showed that the risk
of hospitalization remains high in recipients of implantable car-
dioverter defibrillators (ICDs) or biventricular defibrillators for
cardiac resynchronization therapy (CRT-D)6.
Remote monitoring (RM) of implantable cardiac devices can
facilitate patient access to healthcare and prompt preventive
actions to improve HF outcomes. Several studies demonstrated
the safety of RM and its potential impact on patient manage-
ment, such as the reduction of time to clinical decision,7–11 num-
ber of outpatient visits,12 and inappropriate shocks.13 Whether
these benefits translate into improved clinical outcomes is still
not clear.
The randomized MORE-CARE (MOnitoring Resynchronization
dEvices and CARdiac patiEnts) trial was planned to evaluate
whether RM may be of higher clinical and/or economic value com-
pared with standard follow-up strategies in the management of
systolic HF patients implanted with a CRT-D.
Methods
Study design and patient population
The MORE-CARE is an international, prospective, multicentre, ran-
domized controlled trial involving 61 cardiology centres in nine coun-
tries overall, from Europe and Israel. The trial was designed in
two phases to demonstrate that RM reduces the time from the
onset of a clinically relevant event to clinical decision (Phase 1),
and the incidence of all-cause deaths and major cardiovascular (CV)
and device-related hospitalizations (Phase 2) compared with stan-
dard in-hospital care. Details of the study design and Phase 1 results
have already been described.10,11 In brief, Phase 1 demonstrated that
the median delay from device-detected events to clinical decisions
was reduced in the remote group compared with the control group
[2 (25th–75th percentile, 1–4) days vs. 29 (25th–75th percentile,
3–51) days, P= 0.004]. All patients had received de novo implant of
a Medtronic CRT-D with wireless transmission capabilities within the
last 8 weeks before enrolment. Randomization was stratified by cen-
tres and performed at enrolment using a centralized electronic system.
Patients were randomized 1:1 to undergo remote checks alternating
with in-office follow-ups (Remote arm) or in-office follow-ups alone
(Standard arm).
The trial was registered at www.clinicaltrials.gov under number
NCT00885677.
The study was approved by the Ethics Committee of all participating
centres and was conducted in compliance with the Declaration of



















































































.. Device programming and diagnostic
features
Patients in the Remote arm received a Carelink monitor for scheduled
remote device checks, and automatic alerts for lung fluid accumulation
(OptiVol®), atrial tachyarrhythmia (atrial tachycardia/fibrillation), and
system integrity were enabled. In-office device checks were requested
to re-arm alerts which had been temporarily inactivated due to
previous transmissions. For both arms, audible alerts were disabled,
except alerts for system integrity, low battery voltage, excessive
charge time, and ventricular fibrillation detection/therapy off. Study
flow charts were provided to investigators with the aim to suggest
and guide patient remote management.10
Data collection
Clinical and device data were collected at enrolment and during
scheduled remote checks/in-office visits. Patients in the Remote arm
alternated remote checks with in-office visits every 4 months, while
the Standard arm received in-office visits every 4 months. Additional
data were collected in the case of unscheduled visits or automatic
alerts, medical interventions, adverse events, and study deviations.
Information about patient and caregiver travel (e.g. distance, time,
transport) for in-office visits was also collected.
Study objectives
The primary objective of the MORE-CARE Phase 2 was to eval-
uate the impact of RM on reducing the 2-year incidence of a
composite endpoint including mortality, CV and device-related hos-
pitalizations. Owing to their higher impact on patient morbidity
and healthcare costs, only hospitalizations longer than 48 h were
included in this primary endpoint evaluation. Each reported event
was adjudicated by an independent Event Adjudication Committee
to evaluate whether it could be counted as a study endpoint. The
Committee included three physicians not involved in the trial and
blinded to investigational sites, patient identities, and randomization
assignment.
The secondary endpoints were: (i) the utilization of healthcare
resources for CV reasons, combining any duration of CV hospitaliza-
tions and CV emergency department (ED) admissions together with
both scheduled and unscheduled outpatient visits; (ii) the number of
hospitalizations, ED admissions, and outpatient visits separately; (iii) the
costs related to utilization of healthcare resources for CV and device
reasons both from the healthcare and from the patient perspective;
and (iv) the safety of RM in CRT-D patient management.
The methods adopted for monetary valuations of healthcare costs
are reported in the Supplementary material online (Table S1).
Sample size
The study sample size calculations have already been decribed.10 In
brief, sample size was calculated to compare the 2-year incidence of the
composite endpoint, assuming an event rate of 30% in the Standard arm
and a target of 20% relative hazard reduction in the Remote arm, with
a power of 90% and a confidence interval (CI) of 95%. Up to seven
interim analyses and the final analysis were planned at pre-specified
time points to reach a maximum sample of 1720 patients. With an
expected enrolment rate of 336 patients per year, the estimated study
duration was ∼4 years. The protocol included the option to prolong
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Figure 1 Study flow chart. PIC, patient informed consent form.
or shorten the study duration in the case of a slower or faster rate of
enrolment, respectively.
Statistical analysis
The analysis set was made up of all randomized patients and included
data of the 2-year follow-up period. Crossovers between randomiza-
tion arms were not admitted in the study design; consequently, data
were analysed according to the per-protocol principle. Further details
on statistical analysis are given in the Supplementary material online
(Table S1).
All tests were adjusted for centre and any unbalanced baseline
characteristic. An alpha-level of 0.05 was considered for each test. All
statistical analyses were performed using SAS 9.3 version software (SAS
Institute Inc., Cary, NC, USA).
Early study closure
In July 2014, the Steering Committee decided to terminate the study
prematurely because of a lower than expected enrolment rate (36
patients in the last months) leading to an unrealistic prolongation of
the enrolment period. As a consequence, no additional patients were
enrolled and ongoing patients were followed until 30 April 2015 to
ensure a minimum follow-up of 8 months for the last patients.
Results
Recruitment and population description
From May 2009 to July 2014, a total of 918 patients were enrolled
in the study. One patient withdrew before randomization, 462
patients were randomly assigned to the Remote arm, and 455 to
the Standard arm (Figure 1). Twenty-five and 27 patients from the
Remote and Standard arm, respectively, were excluded from the


















































. evidence of an informed consent form in the centre at the time of
the monitoring visit.
Characteristics of the 865 included patients were balanced
between the study arms (Table 1) except for gender, history
of AF, and atrioventricular block. Mean age at enrolment was
66±10 years, and 76% of patients were men. Forty-four per
cent of patients had ischaemic heart disease, 27% had a history
of AF, and 12% had a history of sustained ventricular arrhyth-
mias. Mean LVEF was 27± 6%. Thirty-eight per cent of patients
were in NYHA class II at the time of enrolment, with clinical
improvement as compared with NYHA class before CRT-D device
implantation (all the patients were in NYHA class III–IV before
implant).
The median follow-up was 24 months for both arms, with an
interquartile range (IQR) of 15–25 months and 14–26 months in
the Remote and Standard arm, respectively. Total exposure time
was 707 patient-years in the Remote arm and 696 patient-years
in the Standard arm. All randomized patients who met the
inclusion/exclusion criteria were included in the analysis until
study exit or death. Follow-up compliance was 94% in both
arms: 1806 (867 in-office visits) out of 1913 (877 in-office vis-
its) in the Remote arm vs. 1789 out of 1912 in the Standard
arm (P= 0.54).
Primary composite endpoint (deaths,
cardiovascular or device-related
hospitalizations)
Overall, 253 patients reached the primary composite endpoint,
130 (29.7%) in the Remote arm and 123 (28.7%) in the Standard
arm: the Kaplan–Meier 2-year risk estimates were 34.3% (95% CI
29.7–39.4) and 32.7% (95% CI 28.2–37.8), respectively (P= 0.89,
Figure 2).
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Table 1 Patient characteristics at enrolment (0–8
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Demographic characteristics
Age (years), mean± SD 66± 11 67±10
Male, n (%) 342 (78.8) 312 (73.1)*




185 (42.8) 193 (45.3)
Myocardial infarction, n
(%)
164 (38.5) 173 (40.7)
History of atrial
arrhythmias, n (%)
126 (29.2) 104 (24.5)
History of AF, n (%) 89 (20.7) 62 (14.7)**
History of sustained
VT/VF, n (%)
53 (12.4) 46 (10.8)
Complete AV block, n
(%)
18 (4.3) 31 (7.4)*
AV node ablation, n (%) 2 (0.5) 2 (0.5)
Left bundle branch
block, n (%)
310 (73.1) 317 (76.0)
QRS (ms), mean± SD 152± 29 155± 29
Valvular alteration, n
(%)
208 (48.5) 194 (46.0)
Previous valvular
surgery, n (%)
41 (9.6) 36 (8.5)
History of syncope, n
(%)
48 (11.3) 52 (12.3)
Diabetes, n (%) 132 (31.3) 154 (37.0)
Hypertension, n (%) 198 (46.2) 171 (40.8)
Previous TIA or stroke,
n (%)
37 (8.7) 26 (6.2)
COPD, n (%) 61 (14.2) 66 (15.6)
NYHA class III or IV at
enrolment, n (%)
265 (62.9) 258 (61.1)
Worsening of HF during
the year before
implant, n (%)
30 (7.2) 22 (5.3)
LVEF (%), mean± SD 27.3± 6.6 27.4± 6.0
Medications at enrolment
Diuretic, n (%) 386 (91.7) 382 (91.2)
Beta-blocker, n (%) 375 (89.1) 370 (88.3)
ACE inhibitor or ARB,
n (%)
347 (82.4) 331 (79.0)
Aldosterone
antagonists
132 (31.5) 128 (30.4)
Antiarrhythmic, n (%) 116 (27.6) 101 (24.1)
Antiplatelet, n (%) 263 (62.5) 250 (59.7)
OAC, n (%) 104 (24.7) 84 (20.0)
Nitrates, n (%) 52 (12.4) 48 (11.5)
*P-value= 0.049; **P-value= 0.020.
HF, heart failure; OAC, oral anticoagulants; TIA, transient ischaemic attack; VF,
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Figure 2 Kaplan–Meier estimates of the primary composite
endpoint.
No significant differences were found in the individual compo-
nents of the primary endpoint (all P> 0.05, Table 2). The most
frequent component of the primary endpoint was CV hospitaliza-
tions, whose Kaplan–Meier 2-year estimates were 27.3% (95% CI
22.9–32.2) in the Remote arm and 26.7% (95% CI 22.4–31.6) in
the Standard arm (P= 0.80).
During the course of the study, 74 patients died: 40 (9.2%) in the
Remote arm and 34 (7.9%) in the Standard arm. The Kaplan–Meier
2-year mortality estimates were 11.2% (95% CI 8.3–15.1) and
9.4% (95% CI 6.8–12.9), respectively (P= 0.59). The 2-year CV
mortality rates were 8.2% (95% CI 5.7–11.7) and 7.8% (95% CI
5.4–11.1), respectively (P= 0.87, Kaplan–Meier curve reported in
the Supplementary material online, Figure S1).
Use of healthcare resources
for cardiovascular reasons
The burden of healthcare resource utilization for CV reasons
was 38% lower in the Remote vs. the Standard arm [incidence
rate ratio (IRR) 0.62, 95% CI 0.58–0.66, P< 0.001, Figure 3],
with 2-year rates of 3.7 (95% CI 3.5–3.9) and 6.0 (95% CI
5.7–6.2) per 100 patients, respectively. As shown in Table 3, 649
hospitalizations were reported, 337 in the Remote arm and 312
in the Standard arm. The all-cause hospitalization rates, estimated
as the 2-year rate per 100 patients, were 96 (95% CI 86–106)
and 90 (95% CI 80–100, p= 0.83), respectively. Hospitalizations
for CV reasons were 197 (111 due to HF) and 200 (103 due
to HF) in the Remote and Standard arm, respectively. During the
study, there were 106 ED admissions (Table 3) not followed by a
hospitalization, with a significantly lower occurrence in the Remote
arm (IRR 0.72, 95% CI 0.53–0.98, P= 0.04). As shown in Table 3,
RM led to a significant reduction in total visits (IRR 0.59, 95%
CI 0.56–0.62, P< 0.001), with more frequent unscheduled visits
compared with the Standard arm (IRR 2.80, 95% CI 2.16–3.63,
P< 0.001).
© 2016 The Authors
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Primary composite endpoint, n (%)
Death or first CV or device-related hospitalization (≥48 h stay) 130 (29.7) 123 (28.7) 1.02 (0.80–1.30) 0.889
Components, n (%)
Death from any cause 40 (9.2) 34 (7.9) 1.13 (0.71–1.80) 0.594
First CV hospitalization 100 (22.9) 97 (22.7) 0.96 (0.73–1.28) 0.796
First device-related hospitalization 17 (3.9) 18 (4.2) 0.89 (0.44–1.79) 0.742
CI, confidence interval; CV, cardiovascular.
Figure 3 Two-year rates per randomization group of scheduled outpatient visits, unscheduled planned and unplanned outpatient visits, and
cardiovascular emergency department admissions and hospitalizations. For each randomization group and type of visit, the total number of
occurrences is displayed beside the corresponding bar. IRR incidence rate ratio.
Costs for cardiovascular
and device-related events from
the National Healthcare System
perspective
Costs related to healthcare resource utilization for CV and
device-related reasons are shown in Table 4. When considering
the estimated costs for the review of device transmissions in the
Remote arm, the cost saving from RM was €2899 per 100 patients















. Costs for visits and device checks from
the perspective of the patient budget
Information about patient and caregiver travel to and from the
hospital showed an average distance between patient’s home and
hospital of 52 km, and the average time required for a one-way
journey was 50 min. In 66% of visits, patients were accompanied
by a relative, and in 5% by an acquaintance or nurse or caregiver.
The majority of journeys (77%) were made by car; other modes
of transportation included local transport by bus (11%), taxi (6%),
and train (3%). The estimated 2-year expenses for patient travelling
© 2016 The Authors
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to the hospital were €373 in the Remote arm and €518 in the
Standard arm (i.e. a cost saving of €145 resulting from RM).
Automatic alert transmissions
In the Remote arm, 5670 alerts were identified and 4683 (82.6%)
were successfully transmitted. Among the 987 failed transmissions,
361 transmissions failed because the patients were already in the
hospital. By excluding these transmissions, the successful transmis-
sion rate rose to 88.2%. Other reasons for transmission failure
were: monitor set off, phone line connection problems, or patient’s
temporary absence from home.
Quality of life
The patient’s quality of life was investigated by means of the Min-
nesota Living With Heart Failure Questionnaire. Baseline values
were comparable between the Remote (26, IQR 12–49) and Stan-
dard (27, IQR 11–46, P= 0.46) arms. The changes in quality of life
from baseline to 16-month follow-up were similar in the Remote
arm (15, IQR 6–30) and Standard arm (10, IQR 3–26, P= 0.29). As
reported in detail in the Supplementary material online (Figure S1),
in both groups quality of life significantly improved at follow-up vs.
baseline (P< 0.001).
Safety issues
Adverse events analysis showed that clinical use of RM did not
raise any safety issue: there were 55 adverse events related to the
implanted system in the Remote arm and 53 in the Standard arm
with 2-year rates of 15.6 (95% CI 11.9–20.3) and 15.2 (95% CI
11.6–19.9) per 100 patients, respectively (P= 0.92).
Discussion
Remote monitoring is proposed as a tool for changing the manage-
ment of HF patients with an implanted device,14 aiming to improve
patient outcome, as well as to reduce the use of resources and
costs for both healthcare systems and patients. The present study
was focused on a specific population of patients with pre-implant
NYHA class III–IV, expected to face a greater number of events
and having complex and time-consuming follow-up needs.
Remote monitoring, mortality
and cardiovascular hospitalizations
The present randomized controlled trial showed that, in patients
with systolic HF and implanted with a CRT-D with automated alerts
for pulmonary congestion and atrial arrhythmias, RM is not asso-
ciated with a benefit on mortality or risk of CV or device-related
hospitalization. These findings are in line with the results of a recent
meta-analysis of 11 randomized controlled trials15 that showed no
significant effect of RM either on all-cause mortality or on cardiac
mortality in HF patients implanted with cardiac implantable electri-



















































































.. intrathoracic impedance and telemedicine-based HF disease man-
agement strategy, showing no effect of telemonitoring on all-cause
death or CV hospitalizations in patients with moderate to severe
HF and implanted with an ICD/CRT-D. The IN-TIME trial is the
only study that showed a positive effect of RM on patient survival,
with a reduced mortality in the remote arm, but without effects
on hospitalizations for worsening of HF17. It is noteworthy that
1-year mortality in the Standard arm of IN-TIME was 1.8-fold that
observed in the Standard arm of MORE-CARE (8.7% vs. 4.8%), thus
indicating differences in patient population characteristics that may
have affected the finding of a beneficial effect on hard outcomes.
Hospitalizations for HF accounted for only around one-third
of all admissions in our study. Real-world data have shown that
co-morbidities significantly and independently affect both all-cause
and HF hospitalizations,6,18 and may therefore mitigate the impact
of RM. It seems clear that, according to evidence from system-
atic reviews,15 recent studies,16 and the present trial, RM of HF
patients, when applied for the purpose of disease management,
does not significantly decrease hospital admissions. Nevertheless,
our data show that RM with advanced diagnostics for HF is safe and
does not compromise outcome. This is in contrast to the use of
audible alerts for transthoracic impedance monitoring, which has




An important aspect for widespread implementation of RM is
reliability of transmissions. In our study, 88.2% of alerts were
properly transmitted, which is an improvement compared with
previous reports.8,16 This may be due to better patient education
together with technical improvements and more experience with
RM compared with earlier studies.
Healthcare resource utilization
In the present study, we decided to analyse clinical and eco-
nomic benefits together, since both are relevant for the healthcare
system.20 The positive results found in the present study are related
to a 41% reduction in scheduled outpatient visits, despite a small
increase in unscheduled visits, but no increase in ED admissions.
This net benefit has interesting implications for re-organization of
care, with financial benefits for both the healthcare system and
the patients. The reduction in scheduled outpatients visits appears
important because most of device follow-ups are routine checks
with no actionable events or device programming.21
Economic analyses focusing on RM of cardiac devices are grow-
ing, but comparisons across studies are challenged by differences in
study design and issues specific to this type of analysis, such as cost-
ing methodologies and the perspective adopted (societal, payer, or
provider).
In the present study, RM had a favourable profile in terms of
costs, from the perspective of both the healthcare system and that
of the patient. This may be a valid reason for implementing RM
despite the lack of impact on hard clinical outcomes. Moreover,
© 2016 The Authors
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RM may be more efficient than traditional in-office follow-up, with
allocation of resources to other tasks.21
A number of reports have evaluated resource use and costs
related to RM.22–29 Reductions in staff time and associated costs
have been consistently reported in several studies,23,29 with the
exception of the EuroEco study,22 where costs were comparable
for device checks based on remote vs. conventional in-office visits.
Results related to costs for healthcare resource utiliza-
tion are variable: Fauchier,25 Raatikainen,23 Zanaboni,24 and
Guédon-Moreau26 reported or assumed savings (due to reduced
visits or hospitalizations, and/or reimbursed transports), whereas
Al-Khatib,27 Burri,28 and Heidbuchel22 did not. This reflects the
variable results of RM studies in terms of outcomes, including
number of visits and hospitalizations. In a recent meta-analysis,
Klersy et al.15 reported that standard follow-up is associated with
higher costs, in the range of 10–55%, as compared with RM,
and that the benefit is likely to be due to a reduction in planned
visits. Our findings are an additional contribution to the field with
regard to savings that can be achieved from the perspective of the
healthcare system. Furthermore, MORE-CARE has also shown
a benefit in terms of patient costs related to transportation.
Another randomized study (REM-HF30) is going to assess RM
in HF when applied to a large number of individuals at nine UK
hospitals, taking into account clinical endpoints (all-cause death or
unplanned hospitalization as the primary endpoint), as well as eco-
nomic endpoints. The latter include the cost per quality-adjusted
life years, with direct costs estimated from the National Health
Service perspective. Both patients with CRT devices and patients
with ICDs are included.30
Finally, costs for performing RM were often not taken into
account in previous economic analyses on RM. This may be
linked to the absence of reimbursement in most countries. In
MORE-CARE, savings in the RM arm were maintained despite
taking into account payment for remote device management.
Limitations
Although the present study was underpowered to evaluate the
primary endpoint because of premature termination, it provides
some data to be evaluated according to the literature, which in
general is in line with our findings, if the primary endpoint and its
components are considered.15
The present analyses excluded some randomized subjects
because those implanted with a CRT-D, or unable to use the Care-
Link System, were not considered in the analysis set. Despite having
provided flow charts for managing specific alerts, clinical practice
was likely to have varied between different study centres. This
reflects daily practice and the complexity of HF management. Fur-
thermore, automatic alerts for HF monitoring were programmed
only for AF and thoracic impedance, with no activation for sev-
eral parameters—heart rate variability, nocturnal heart rate, and
patient activity—that have recently been the subject of investiga-
tion for improving prediction of HF worsening.31
The economic benefit was based on some assumptions and on
tariffs derived from the Italian context, where most of the patients



















































































.. be higher in other countries,32 the extent of monetary savings
that could be achieved may be underestimated by the current
analysis. Finally, in our economic analysis we did not consider the
perspective of the provider, but focused on that of the healthcare
system and the patient.
Conclusions
In HF patients implanted with a CRT-D, RM did not reduce
mortality or risk of CV or device-related hospitalization. Despite
the lack of benefit on clinical outcomes, the use of RM had a
positive impact on the use of healthcare resources, with a 41%
reduction of in-office visits, without compromising patient safety.
The favourable profile in terms of cost savings of RM vs. standard
follow-up emerged from the perspective of the healthcare system
as well as from that of the patient.
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